Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANACHE 02: Risk-adapted Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma
NCT07044453Phase 3Recruiting
- Sponsor
- Rouen University Hospital
- Start
- Dec 2025
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Rouen University Hospital. Primary endpoints: Disease Free Survival at 5 years and Overall Survival at 7 years. Started Dec 2025; status: recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07044453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044453.